Cismaru, Anca LilianaRudin, DeborahIbañez, LuisaLiakoni, EvangeliaBonadies, NicolasKreutz, ReinholdCarvajal, AlfonsoLucena, Maria IsabelMartin, JavierSancho Ponce, EstherMolokhia, MariamEriksson, NiclasEuDAC Collaborators,Krähenbühl, StephanLargiadèr, Carlo RHaschke, ManuelHallberg, PärWadelius, MiaAmstutz, Ursula2023-02-092023-02-092020-10-29http://hdl.handle.net/10668/16529Agranulocytosis is a rare yet severe idiosyncratic adverse drug reaction to metamizole, an analgesic widely used in countries such as Switzerland and Germany. Notably, an underlying mechanism has not yet been fully elucidated and no predictive factors are known to identify at-risk patients. With the aim to identify genetic susceptibility variants to metamizole-induced agranulocytosis (MIA) and neutropenia (MIN), we conducted a retrospective multi-center collaboration including cases and controls from three European populations. Association analyses were performed using genome-wide genotyping data from a Swiss cohort (45 cases, 191 controls) followed by replication in two independent European cohorts (41 cases, 273 controls) and a joint discovery meta-analysis. No genome-wide significant associations (penAttribution 4.0 Internationalhttp://creativecommons.org/licenses/by/4.0/dipyronedrug-induced agranulocytosisgenome-wide association studymetamizolepharmacogeneticsAdultAgedAged, 80 and overAgranulocytosisBiomarkers, PharmacologicalCase-Control StudiesDipyroneEuropeFemaleGenetic Predisposition to DiseaseGenome-Wide Association StudyGermanyHumansMaleMiddle AgedNeutropeniaRetrospective StudiesSwitzerlandresearch article33138277open access10.3390/genes111112752073-4425PMC7716224https://www.mdpi.com/2073-4425/11/11/1275/pdf?version=1603982888https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7716224/pdf